Department of Addiction Medicine, St Vincent's Hospital, Melbourne, Australia.
J Clin Psychopharmacol. 2012 Apr;32(2):266-8. doi: 10.1097/JCP.0b013e31824929b2.
Alcohol dependence is associated with a wide array of physical and psychiatric complications and is a major cause of morbidity and mortality worldwide. Recent randomized trials of baclofen, with a total daily dose 30 mg administered in 3 divided doses, have supported its efficacy in reducing craving and promoting abstinence from alcohol. Individual case studies support a possible increased effect at higher doses for treatment-resistant patients. Here, we report on 4 alcohol-dependent patients resistant to standard treatments who responded to higher doses of baclofen ranging from 75 to 125 mg daily. Further research into the use of high-dose baclofen for treatment-resistant alcohol dependence is warranted.
酒精依赖与广泛的身体和精神并发症有关，是全球发病率和死亡率的主要原因。最近的巴氯芬随机试验，每日总剂量 30 毫克，分 3 次给药，支持其在减少渴望和促进酒精戒断方面的疗效。个别病例研究支持对治疗抵抗患者使用更高剂量可能会有更好的效果。在这里，我们报告了 4 例对标准治疗有抵抗的酒精依赖患者，他们对每日剂量从 75 到 125 毫克不等的更高剂量的巴氯芬有反应。进一步研究高剂量巴氯芬治疗治疗抵抗性酒精依赖是有必要的。
